[Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil].
Adefovir dipivoxil is an analogue nucleotide recently approved for the treatment of chronic hepatitis HBV-related. Some recent studies have evidenced that treatment with 10 mg/die orally with adefovir dipivoxil is efficacy and well tolerate in patients with chronic hepatitis B, both HBeAg-positive and anti-HBe-positive, with LAM-resistance. Also, adefovir dipivoxil effectively suppresses lamivudine-resistant HBV in patients with chronic hepatitis B after liver transplantation, compensated or decompensated liver disease and co-infection with HIV. Other studies are needed to evaluate the efficacy of prolonged treatment in relation to emerge of adefovir-resistant HBV mutants.
Palumbo
Emilio
E
emipalu2003@yahoo.it
D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006515:Hepatitis B virus / Q000187:drug effects*; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000998:Antiviral Agents; D063065:Organophosphonates; D000225:Adenine; C106812:adefovir dipivoxil